Consensus on the use of immunomodulating drugs in the treatment of EM;Consenso sobre el uso de drogas inmunomoduladoras en el tratamiento de la EM

Revista Neurologica Argentina

Volumn 25, Issue 4, 2000, Pages 142-145

  Correale, J ^a   Patrucco, L ^a   Cristiano, E ^a   Bettinelli, R ^a   Carra A ^a   Deri, N ^a   Fernandez Liguori, N ^a   Garcea, O ^a   Onaha, P ^a   Perez, W ^a   Rotta Escalante, R ^a   San Pedro, E ^a   Savino, A ^a   Tenembaum, S ^a  

^a FLENI   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ARGENTINA; ARTICLE; DRUG EFFECT; DRUG INDICATION; DRUG USE; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE;

EID: 0034425292     PISSN: 03250938     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Defining the clinical course of multiple sclerosis: Results of an international survey
2. Immunology of multiple sclerosis and experimental allergic encephalomyelitis
3. Pathogenesis of multiple sclerosis: Relationship to therapeutic strategies
4. Pathology of multiple sclerosis
5. Axonal transection in multiple sclerosis lesions
6. Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis: Results of a longitudinal MR spectroscopy study
7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
8. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
9. Interferon beta-1b in the treatment of multiple sclerosis. Final outcome of the ramdomized controlled trial
10. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
11. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical affect of multiple sclerosis relapse rate and degree of disability
12. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing -remitting multiple sclerosis (RRMS): A multicenter randomised, double blind, placebo controlled study extended by open label treatment
13. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
14. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
15. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
16. Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis
17. PRISMS 4-year results: Evidence of clinical dose effect of interferon beta-1a in relapsing MS
18. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
19. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
20. Placebo-controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
21. Effect of interferon beta-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
22. "Relapsing" vs "Nonrelapsing" SPMS: Different prognosis and response to interferon therapy in the SPECTRIMS Study
23. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomised controlled trial
24. Natural history of multiple sclerosis
25. Intratecal production of IgG antibodies to neurofilament-light (NF-L) is elevated in patients with primary and secondary progressive multiple sclerosis
26. Diversity and plasticity of self recognition during the development of multiple sclerosis
27. Contrast enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis
28. Interferon beta-1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multicenter randomised, double blind placebo controlled study
29. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
30. Consensus statement of the Canadian MS clinics network on: The use of disease modifying agents in multiple sclerosis
31. Escalating therapy of multiple sclerosis
32. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols